Dr. Martin Highlights Recent Myeloma Research at EHA 2024

Thomas Martin, MD, Clinical Research Director of the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses exciting research in newly diagnosed multiple myeloma (MM) presented at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain.

Specifically, Dr. Martin highlighted research in quadruplet therapy, chimeric antigen receptor T-cell therapy, and bispecific T-cell engagers.

“It’s been a very exciting meeting for newly diagnosed, early relapse, and for the late immunotherapies of [MM],” he said.